{"id":42941,"date":"2026-01-06T11:03:00","date_gmt":"2026-01-06T04:03:00","guid":{"rendered":"https:\/\/thaipropertynews.com\/feeds\/?p=42941"},"modified":"2026-01-06T11:03:00","modified_gmt":"2026-01-06T04:03:00","slug":"esco-aster-signs-exosome-clinical-cgmp-manufacturing-contract-with-shine-on-biomedical-for-a-novel-first-in-class-hla-g-targeting-exosome-drug-delivery-platform","status":"publish","type":"post","link":"https:\/\/thaipropertynews.com\/feeds\/?p=42941","title":{"rendered":"Esco Aster Signs Exosome Clinical cGMP Manufacturing Contract With Shine-On Biomedical For A Novel First-In-Class HLA-G Targeting Exosome Drug Delivery Platform"},"content":{"rendered":"

SINGAPORE<\/span><\/span>, Jan. 6, 2026<\/span><\/span> \/PRNewswire\/ — Esco Aster, a vertically integrated cell and derivatives CRDMO based at JTC LaunchPad Singapore, announced CMC manufacturing support for Shine-On Biomedical’s HLA-G targeted exosome program. \u00a0Shine-On Biomedical sponsored\u00a0Esco Aster in 2023 for cGMP services, starting with high-yield exosome development using Esco Aster’s cell line platform. The technical reports of process, analytical, and formulation development, exosome drug loading, GMP engineering runs, and stability studies\u00a0supported\u00a0Shine-On’s IND submission. The IND was cleared by the U.S. FDA in Q1 2025. \u00a0<\/p>\n

Furthermore, Esco Aster is providing technical services for exploratory exosome loading feasibility studies per Shine-On’s instruction. Shine-On Biomedical is an emerging innovator in exosome-based drug delivery. \u00a0<\/p>\n

ShineOn’s proprietary product, SOB100, a HLA-G targeted exosome drug delivery carrier, has passed the U.S. FDA IND review\u00a0and ongoing Phase I study, making it as a first-in-class\u2013potential HLA-G targeted exosome platform for drug\u00a0development. \u00a0<\/p>\n

Statement From Hung-Che Chiang<\/span>, General Manager of Shine-On Biomedical <\/b><\/p>\n

“Preclinical studies have shown promising biodistribution characteristics supporting further exploration across small-molecule, nucleic acid, and protein-based payloads.”<\/p>\n

In parallel, Esco Aster, providing Mitosis\u2122 Enterprise Solutions to support potential future evaluation of single-use cGMP workflows at China Medical University Hospital.\u00a0<\/p>\n

This collaboration strengthens Esco Aster’s position as Singapore’s<\/span> first fully homegrown CRDMO offering end-to-end engineered cancer exosome development\u2014from cell line creation to GMP manufacturing using its patented 3D Tide Motion\u2122 bioreactor. This technology lowers COGS by enabling multiple conditioned media harvests per run. Esco Aster also co-develops autologous cell therapy programs in ASEAN, including a T-cell reactivation platform targeting non-G12C KRAS mutation NSCLC.<\/p>\n

Esco Aster supports Asia-Pacific<\/span> innovators through biomanufacturing scale-up, market access, and commercialization across South Asia<\/span>, ASEAN, and Oceania\u2014a region valued at ~USD 10.5 trillion<\/span> GDP with ~2.6 billion people. Supported by a network of medical centres and clinician-scientists, Esco Aster facilitates IIT and FIM studies, especially in Australia<\/span>, where R&D incentives lower costs. The company advances its “One World BioSolutions for One Health” vision, enabling high yield at low GMP cost to strengthen Singapore’s<\/span> and Asia’s<\/span> bioeconomy.<\/p>\n

Contacts
<\/b>Esco Aster Pte. Ltd.
<\/b>mail@escoaster.com<\/a>
Website: https:\/\/escoaster.com\/<\/a><\/p>\n

Shine-On Biomedical Co., Ltd.<\/b>
service@shineon-bio.com<\/a>\u00a0
Website: https:\/\/en.shineon-bio.com\/<\/a><\/p>\n

\u00a9 2025 Esco Aster Pte. Ltd. and Shine-On Biomedical Co., Ltd. All rights reserved.<\/p>","protected":false},"excerpt":{"rendered":"

<\/p>\n

SINGAPORE<\/span><\/span>, Jan. 6, 2026<\/span><\/span> \/PRNewswire\/ — Esco Aster, a vertically integrated cell and derivatives CRDMO based at JTC LaunchPad Singapore, announced CMC manufacturing support for Shine-On Biomedical’s HLA-G targeted exosome program. \u00a0Shine-On Biomedical sponsored\u00a0Esco Aster in 2023 for cGMP services, starting with high-yield exosome development using Esco Aster’s cell line platform. The technical reports of process, analytical, and formulation development, exosome drug loading, GMP engineering runs, and stability studies\u00a0supported\u00a0Shine-On’s IND submission. The IND was cleared by the U.S. FDA in Q1 2025. \u00a0<\/p>\n

Furthermore, Esco Aster is providing technical services for exploratory exosome loading feasibility studies per Shine-On’s instruction. Shine-On Biomedical is an emerging innovator in exosome-based drug delivery. \u00a0<\/p>\n

ShineOn’s proprietary product, SOB100, a HLA-G targeted exosome drug delivery carrier, has passed the U.S. FDA IND review\u00a0and ongoing Phase I study, making it as a first-in-class\u2013potential HLA-G targeted exosome platform for drug\u00a0development. \u00a0<\/p>\n

Statement From Hung-Che Chiang<\/span>, General Manager of Shine-On Biomedical <\/b><\/p>\n

“Preclinical studies have shown promising biodistribution characteristics supporting further exploration across small-molecule, nucleic acid, and protein-based payloads.”<\/p>\n

In parallel, Esco Aster, providing Mitosis\u2122 Enterprise Solutions to support potential future evaluation of single-use cGMP workflows at China Medical University Hospital.\u00a0<\/p>\n

This collaboration strengthens Esco Aster’s position as Singapore’s<\/span> first fully homegrown CRDMO offering end-to-end engineered cancer exosome development\u2014from cell line creation to GMP manufacturing using its patented 3D Tide Motion\u2122 bioreactor. This technology lowers COGS by enabling multiple conditioned media harvests per run. Esco Aster also co-develops autologous cell therapy programs in ASEAN, including a T-cell reactivation platform targeting non-G12C KRAS mutation NSCLC.<\/p>\n

Esco Aster supports Asia-Pacific<\/span> innovators through biomanufacturing scale-up, market access, and commercialization across South Asia<\/span>, ASEAN, and Oceania\u2014a region valued at ~USD 10.5 trillion<\/span> GDP with ~2.6 billion people. Supported by a network of medical centres and clinician-scientists, Esco Aster facilitates IIT and FIM studies, especially in Australia<\/span>, where R&D incentives lower costs. The company advances its “One World BioSolutions for One Health” vision, enabling high yield at low GMP cost to strengthen Singapore’s<\/span> and Asia’s<\/span> bioeconomy.<\/p>\n

Contacts
<\/b>Esco Aster Pte. Ltd.
<\/b>mail@escoaster.com<\/a>
Website: https:\/\/escoaster.com\/<\/a><\/p>\n

Shine-On Biomedical Co., Ltd.<\/b>
service@shineon-bio.com<\/a>\u00a0
Website: https:\/\/en.shineon-bio.com\/<\/a><\/p>\n

\u00a9 2025 Esco Aster Pte. Ltd. and Shine-On Biomedical Co., Ltd. All rights reserved.<\/p>\n

<\/p>\n","protected":false},"author":1,"featured_media":0,"comment_status":"open","ping_status":"open","sticky":false,"template":"","format":"standard","meta":{"rop_custom_images_group":[],"rop_custom_messages_group":[],"rop_publish_now":"initial","rop_publish_now_accounts":[],"rop_publish_now_history":[],"rop_publish_now_status":"pending","footnotes":""},"categories":[1],"tags":[],"class_list":["post-42941","post","type-post","status-publish","format-standard","has-post-thumbnail","hentry","category-uncategorized"],"_links":{"self":[{"href":"https:\/\/thaipropertynews.com\/feeds\/index.php?rest_route=\/wp\/v2\/posts\/42941","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/thaipropertynews.com\/feeds\/index.php?rest_route=\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/thaipropertynews.com\/feeds\/index.php?rest_route=\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/thaipropertynews.com\/feeds\/index.php?rest_route=\/wp\/v2\/users\/1"}],"replies":[{"embeddable":true,"href":"https:\/\/thaipropertynews.com\/feeds\/index.php?rest_route=%2Fwp%2Fv2%2Fcomments&post=42941"}],"version-history":[{"count":0,"href":"https:\/\/thaipropertynews.com\/feeds\/index.php?rest_route=\/wp\/v2\/posts\/42941\/revisions"}],"wp:attachment":[{"href":"https:\/\/thaipropertynews.com\/feeds\/index.php?rest_route=%2Fwp%2Fv2%2Fmedia&parent=42941"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/thaipropertynews.com\/feeds\/index.php?rest_route=%2Fwp%2Fv2%2Fcategories&post=42941"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/thaipropertynews.com\/feeds\/index.php?rest_route=%2Fwp%2Fv2%2Ftags&post=42941"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}